Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642254 | 0.85 | LMNA (0.52) | LCKLMNAADORA3TSHRMC4R | |
| Hydrochloric Acid SCHEMBL30527997 | 0.83 | LMNA (0.50) | LCKLMNAADORA3TSHRMC4R | |
| SCHEMBL24184895 | 0.79 | ALDH1A1 (0.40) | KMOKMT2AL3MBTL1MMP13 | |
| SCHEMBL232129 | 0.79 | KMO (0.52) | KMOKDM4E | |
| SCHEMBL3032664 | 0.77 | LMNA (0.40) | LCKLMNAADORA3TSHRMC4R | |
| SCHEMBL15228305 | 0.77 | KMO (0.50) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL2774815 | 0.76 | SIRT6 (0.50) | LCKLMNAADORA3TSHRMC4R | |
| SCHEMBL22544553 | 0.76 | LMNA (0.48) | LCKLMNAADORA3TSHRMC4R | |
| SCHEMBL31196442 | 0.76 | SIRT6 (0.50) | LCKLMNAADORA3TSHRMC4R | |
| SCHEMBL8148229 | 0.76 | SIRT6 (0.41) | LCKLMNAADORA3TSHRMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | LCK 67/4885LMNA 3725/4885ADORA3 4250/4885 |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | LCK 67/4885LMNA 3725/4885ADORA3 4250/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | LCK 1154/4885LMNA 3819/4885ADORA3 89/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | LCK 4582/4885LMNA 1854/4885ADORA3 3999/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | LCK 4582/4885LMNA 1854/4885ADORA3 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.